DE60025921D1 - Benzodiazepine mit sofortiger wirkung - Google Patents

Benzodiazepine mit sofortiger wirkung

Info

Publication number
DE60025921D1
DE60025921D1 DE60025921T DE60025921T DE60025921D1 DE 60025921 D1 DE60025921 D1 DE 60025921D1 DE 60025921 T DE60025921 T DE 60025921T DE 60025921 T DE60025921 T DE 60025921T DE 60025921 D1 DE60025921 D1 DE 60025921D1
Authority
DE
Germany
Prior art keywords
sedation
compounds
present
benzodiazepine
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60025921T
Other languages
English (en)
Other versions
DE60025921T2 (de
Inventor
Paul L Feldman
David Kendall Jung
Istvan Kaldor
Gregory J Pacofsky
Jeffrey A Stafford
Jeffrey H Tidwell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Paion UK Ltd
Original Assignee
Cenes Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cenes Ltd filed Critical Cenes Ltd
Application granted granted Critical
Publication of DE60025921D1 publication Critical patent/DE60025921D1/de
Publication of DE60025921T2 publication Critical patent/DE60025921T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/22—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Gyroscopes (AREA)
  • Surface Treatment Of Glass Fibres Or Filaments (AREA)
  • Paper (AREA)
DE60025921T 1999-05-14 2000-05-12 Benzodiazepine mit sofortiger wirkung Expired - Lifetime DE60025921T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9911152 1999-05-14
GBGB9911152.8A GB9911152D0 (en) 1999-05-14 1999-05-14 Short-acting benzodiazepines
PCT/US2000/013134 WO2000069836A1 (en) 1999-05-14 2000-05-12 Short-acting benzodiazepines

Publications (2)

Publication Number Publication Date
DE60025921D1 true DE60025921D1 (de) 2006-04-20
DE60025921T2 DE60025921T2 (de) 2006-10-26

Family

ID=10853415

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60025921T Expired - Lifetime DE60025921T2 (de) 1999-05-14 2000-05-12 Benzodiazepine mit sofortiger wirkung

Country Status (11)

Country Link
EP (1) EP1183243B1 (de)
JP (4) JP3773792B2 (de)
AT (1) ATE317390T1 (de)
AU (1) AU4846300A (de)
DE (1) DE60025921T2 (de)
DK (1) DK1183243T3 (de)
ES (1) ES2258008T3 (de)
GB (1) GB9911152D0 (de)
HK (1) HK1042296B (de)
PT (1) PT1183243E (de)
WO (1) WO2000069836A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02001340A (es) * 1999-08-05 2004-07-16 Prescient Neuropharma Inc Compuestos novedosos 1,4-benzodiazepina y derivados de los mismos.
GB0613693D0 (en) 2006-07-10 2006-08-16 Cenes Ltd Benzodiazepine salts (3)
PL2081921T3 (pl) * 2006-07-10 2011-03-31 Paion Uk Ltd Krótko działające sole benzodiazepiny i ich formy polimorficzne
EP2305647A1 (de) * 2009-09-18 2011-04-06 PAION UK Limited Verfahren zur Herstellung von 3-[(4S)-8-brom-1-methyl-6-(2-pyridinyl)-4 H-imidazo[1,2-a][1,4]benzodiazepin-4-yl]propionsäuremethylester oder das Benzensulfonatsalz davon und in diesem Prozess nützliche Verbindungen
EP2450039A1 (de) 2010-11-08 2012-05-09 PAION UK Ltd. Dosierschema zur Sedierung mit CNS 7056 (Remimazolam)
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
US9422292B2 (en) 2011-05-04 2016-08-23 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
EP2721031B1 (de) 2011-06-17 2016-01-20 Constellation Pharmaceuticals, Inc. Bromodomainhemmer und ihre verwendungen
CN102964349A (zh) * 2011-08-31 2013-03-13 江苏恒瑞医药股份有限公司 苯并二氮杂*衍生物的托西酸盐及其多晶型、它们的制备方法和用途
ES2651389T3 (es) * 2012-05-22 2018-01-26 Paion Uk Limited Composiciones que comprenden benzodiazepinas de acción corta
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
EP2864336B1 (de) 2012-06-06 2016-11-23 Constellation Pharmaceuticals, Inc. Benzo[b]isoxazolazepinbromdomänenhemmer und verwendungen davon
SG11201501358SA (en) * 2012-08-31 2015-04-29 Paion Uk Ltd Method for administering hypnotic/sedative agent
AR094963A1 (es) * 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
CN103202815B (zh) * 2013-05-05 2014-09-24 李友香 治疗精神疾病的注射剂
CN104146970A (zh) * 2013-05-05 2014-11-19 王元青 治疗精神疾病的冻干粉针剂
CN103232454A (zh) * 2013-05-05 2013-08-07 王元青 治疗精神疾病的药物
CN103230595B (zh) * 2013-05-05 2014-10-08 李友香 治疗精神疾病的组合物
CA2952830C (en) 2014-06-20 2022-11-01 Constellation Pharmaceuticals, Inc. Crystalline forms of 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide
US9994578B2 (en) 2014-07-23 2018-06-12 Jiangsu Nhwaluokang Pharmceutical Research And Development Co., Ltd Benzodiazepine derivative and use thereof
CN106892924B (zh) * 2015-12-17 2021-01-08 四川科伦博泰生物医药股份有限公司 短效苯并二氮*衍生物、其制备方法及其用途
CN107266452A (zh) * 2016-04-08 2017-10-20 四川科伦药物研究院有限公司 苯并二氮杂*衍生物的盐及其晶体形式、制备方法和用途
BR112018071082A2 (pt) 2016-04-14 2019-02-05 Paion Uk Ltd benzodiazepinas nasais e inaladas oralmente
JP7013446B2 (ja) 2016-08-16 2022-02-15 ユーダブリューエム・リサーチ・ファウンデーション，インコーポレーテッド Ｇａｂａ（ａ）受容体モジュレーター、及び、喘息における気道過敏及び炎症を抑制するための方法
CN108503644B (zh) * 2016-12-09 2019-06-14 成都倍特药业有限公司 一种苯并二氮杂*衍生物的氢溴酸盐及其制备方法和用途
CN108264499B (zh) * 2017-01-04 2020-10-20 江苏恒瑞医药股份有限公司 一种苯并二氮杂*衍生物的制备方法
WO2018196662A1 (zh) * 2017-04-28 2018-11-01 四川科伦博泰生物医药股份有限公司 包含苯并二氮䓬类化合物的注射用组合物及其制备方法
CN108948018B (zh) * 2017-05-17 2021-03-30 四川科伦博泰生物医药股份有限公司 苯并二氮*衍生物及其盐和相关晶体形式、制备方法和用途
ES2697918A1 (es) 2017-07-28 2019-01-29 Moehs Iberica Sl Procedimiento para preparar ester metilico del acido 3-[(3s)-7-bromo-2-oxo-5-(piridin-2-il)-2,3-dihidro-1h-[1,4]-benzodiazepin-3-il] propionico, y compuestos utiles en ese procedimiento
ES2709298B2 (es) 2017-10-13 2019-08-21 Moehs Iberica Sl Procedimiento para preparar metil ester de acido 3-[(4s)-8-bromo-1-metil-6-(piridin-2-il)-4h-imidazo[1,2-a][1,4]benzodiazepin-4-il]-propionico, y compuestos utiles en ese procedimiento
RU2701557C2 (ru) * 2017-11-24 2019-09-30 Общество С Ограниченной Ответственностью "Инновационные Фармакологические Разработки" (Ооо "Ифар") Производные 1,4-бензодиазепин-2-она и их применение
CN108003164A (zh) * 2017-12-15 2018-05-08 宜昌人福药业有限责任公司 苯并二氮杂*类化合物
CN107868088A (zh) * 2017-12-15 2018-04-03 宜昌人福药业有限责任公司 苯并二氮杂*类氮氧化物
CN108084187A (zh) * 2017-12-15 2018-05-29 宜昌人福药业有限责任公司 苯并二氮杂*类氢化物
CN108033964B (zh) * 2017-12-28 2021-02-09 杭州奥默医药股份有限公司 一种吡啶基咪唑并苯并二氮杂卓丙酸酯化合物及其合成和应用
MX2020008465A (es) 2018-02-13 2020-12-07 Jiangsu Nhwaluokang Pharmaceutical Res And Development Co Ltd Clorhidrato de derivado de benzodiazepina y forma cristalina, método de preparación y aplicación del mismo.
WO2020259602A1 (zh) * 2019-06-28 2020-12-30 四川大学华西医院 苯二氮卓类化合物及其制备方法和在医药上的作用
ES2803099B2 (es) 2019-07-22 2021-11-08 Moehs Iberica Sl Procedimiento de obtención de besilato de remimazolam amorfo
KR102526590B1 (ko) * 2020-06-19 2023-04-28 하나제약 주식회사 3-[(4S)-8-브로모-1-메틸-6-(2-피리디닐)-4H-이미다조[1,2-a][1,4]벤조디아제핀-4-일]프로피온산 메틸 에스테르의 제조방법
CN112358483A (zh) * 2020-11-09 2021-02-12 中国药科大学 一类新型苯并二氮*类化合物、其制备方法及其用途
CN114644612B (zh) * 2020-12-17 2023-04-28 成都苑东生物制药股份有限公司 一种苯二氮杂类神经抑制剂中间体化合物的制备方法
WO2023083191A1 (zh) * 2021-11-09 2023-05-19 四川大学华西医院 苯二氮卓类化合物及其制备方法和在医药上的用途
WO2023194945A1 (en) * 2022-04-08 2023-10-12 Fresenius Kabi Oncology Ltd. An improved process for the preparation of remimazolam
CN115322144B (zh) * 2022-08-30 2024-05-24 上海药坦药物研究开发有限公司 一种2-(2-氨基-5-溴-苯甲酰基)吡啶的制备方法
CN115385891A (zh) * 2022-09-06 2022-11-25 上海药坦药物研究开发有限公司 一种瑞马唑仑中间体的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR6915069D0 (pt) * 1969-02-28 1973-08-16 Upjohn Co Compostos organicos e processo
DE2156472A1 (de) * 1970-11-23 1972-05-31 Ciba-Geigy Ag, Basel (Schweiz) Verfahren zur Herstellung von neuen Diazepinderivaten
FR2183716A1 (en) * 1972-05-05 1973-12-21 Centre Etd Ind Pharma Substd-6-phenyl-4h-imidazo (1,2-a)-1,4-benzo diazepines - - tranquillisers anxiolytics,sedatives and muscle-relaxants
IE41197B1 (en) * 1973-05-29 1979-11-07 Squibb & Sons Inc 4h-s-triazolo (4,3-a)(1,5)benzodiazepin-5-ones
CH608234A5 (en) * 1974-08-30 1978-12-29 Crc Ricerca Chim Process for the preparation of lithium salts of 1,4-benzodiazepines
DE2900017A1 (de) * 1978-01-10 1979-07-12 Clin Midy 3-alkoxycarbonyl-benzodiazepin- derivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
MC1528A1 (fr) * 1982-07-21 1984-04-13 Hoffmann La Roche Imidazobenzodiazepines
IT1165588B (it) * 1983-03-23 1987-04-22 Medosan Ind Biochimi 1,4 benzodiazepine terapeuticamente attive
ATE132974T1 (de) * 1986-10-24 1996-01-15 Abbott Lab Test, indikatoren, immunogene und antikörper für benzodiazepine
US5220017A (en) * 1991-04-10 1993-06-15 Merck & Co., Inc. Cholecystokinin antagonists
JPH07304755A (ja) * 1994-05-12 1995-11-21 Yamanouchi Pharmaceut Co Ltd 縮合ジアゼピン誘導体
US5834464A (en) * 1994-11-18 1998-11-10 Merck & Co., Inc. Imidazolinobenzodiazepines
CA2257948A1 (en) * 1996-06-28 1998-01-08 Merck & Co., Inc. Antiarrhythmic combinations of selective iks antagonists with beta-adenergic blocking agents
EP0881235A1 (de) * 1997-05-26 1998-12-02 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Phosphor Ylide, Herstellung und Verwendung zu schwachnukleophilen starkbasischen Verbindungen

Also Published As

Publication number Publication date
JP4769562B2 (ja) 2011-09-07
ES2258008T3 (es) 2006-08-16
GB9911152D0 (en) 1999-07-14
HK1042296A1 (en) 2002-08-09
PT1183243E (pt) 2006-06-30
JP3773792B2 (ja) 2006-05-10
WO2000069836A1 (en) 2000-11-23
EP1183243A1 (de) 2002-03-06
DE60025921T2 (de) 2006-10-26
DK1183243T3 (da) 2006-06-12
HK1042296B (zh) 2006-08-25
ATE317390T1 (de) 2006-02-15
JP4769760B2 (ja) 2011-09-07
EP1183243B1 (de) 2006-02-08
JP4769759B2 (ja) 2011-09-07
JP2007197468A (ja) 2007-08-09
JP2007197469A (ja) 2007-08-09
JP2002544266A (ja) 2002-12-24
JP2006151984A (ja) 2006-06-15
AU4846300A (en) 2000-12-05

Similar Documents

Publication Publication Date Title
DE60025921D1 (de) Benzodiazepine mit sofortiger wirkung
KR940014328A (ko) 인돌린 화합물
DE602004006165D1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
ATE316076T1 (de) Benzimidazol-derivate und diese enthaltende pharmazeutische zusammensetzungen
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
RU96119255A (ru) 4-гетероциклил-замещенные производные хиназолина, способ их получения и их применение в качестве противоракового средства
FR2714378B1 (fr) Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.
UA93393C2 (uk) 1,3-діоксанкарбонові кислоти
WO2006016689A1 (ja) Ｅｐ４アゴニストを含有してなる下部尿路系疾患の予防および／または治療剤
BRPI0507657A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
EA200802173A1 (ru) Производные терфенила для лечения болезни альцгеймера
ES2118222T3 (es) Inhibidores de 5-alfa-testosterona reductasa.
SE0102055D0 (sv) New Compounds
PL316563A1 (en) Application of derivatives of carboxylic acids as therapeutic agents
FI964482A (fi) Amidijohdannaisia ja niiden käyttö lääkkeenä
ATE415965T1 (de) Verwendung von verzweigtkettigen fettsäuren und ihrer derivate zur schmerzbehandlung
BR0111767A (pt) Composições analgésicas e anti-inflamatórias contendo inibidores de cox-2, seu uso e método para potencializar um composto analgésico
EA200900068A1 (ru) Способ получения формы i кандесартана цилексетила
AU2003276514A1 (en) 4-imidazol-1-ylmethyl-pyrimidine derivatives_as ligands for gabaa receptors
EP1806136A4 (de) Medizinische zusammensetzung zur prävention des übergangs zu einer operativen behandlung bei prostatahypertrophie
ATE166053T1 (de) Carbaminsäure estern derivate und deren verwendung in heilmittel
ATE303148T1 (de) Chinolin-harnstoff-derivate zur behandlung von entzugssyndrom und durch entzugssyndrom verursachten gehirnschaden
EE200100193A (et) 3-(1H-imidasool-4-ülmetüül)-indaan-5-ol'i kasutamine intraspinaalselt, teekasiseselt või epiduraalselt manustatava ravimi tootmises
PT1293198E (pt) Dispositivo de administracao transdermica para o tratamento de patologias do tracto urinario
CY1115013T1 (el) Διαμορφωτες υποδοχεα 7 που προσομοιαζει toll

Legal Events

Date Code Title Description
8364 No opposition during term of opposition